common.study.topics.clinical

Helping People Survive with Bladder Urothelial Carcinoma

common.study.values.description

A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival

The investigators would like to compare the progression free survival, overall survival, quality of life, and safety outcomes of patients receiving versus not receiving a 2nd transurethral resection of bladder tumor.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Procedure - re-TURBT

2nd bladder biopsy within 4-6 weeks of initial biopsy

Drug - 6 weeks BCG instillation

standard 6 weeks of BCG induction

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Pilot, Single-centre, Randomized, 5-year, Parallel-group, Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival

common.study.values.clinical-trial-id

NCT03266900

participant.views.study.view.id

9av4Vd